CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma

被引:0
|
作者
Kaihua Tang
Xiaoting Li
Jianwen Mo
Yixuan Chen
Chengyu Huang
Ting Li
Tianjian Luo
Zhijian Zhong
Yongqiang Jiang
Dengfeng Yang
Weiliang Mo
机构
[1] YuanDong International Academy of Life Sciences,Department of Basic Science
[2] Guangxi Academy of Sciences,Biology Institute
[3] Guangxi Beibu Gulf Marine Research Center,Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry
[4] Guangxi Academy of Sciences,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The prevalence and mortality of hepatocellular carcinoma (HCC) are still increasing. This study aimed to identify potential therapeutic targets related to patient prognosis. Data were downloaded from TCGA, GSE25097, GSE36376, and GSE76427 datasets. Differential analysis and enrichment analysis were performed in HCC. Cell deaths were evaluated, and least absolute shrinkage and selection operator regression (LASSO) regression was analyzed to screen candidate genes. Additionally, immune cell infiltration in HCC was assessed. We identified 4088 common DEGs with the same direction of differential expression in all four datasets, they were mainly enriched in immunoinflammation and cell cycle pathways. Apoptosis was significantly suppressed in HCC in GSEA and GSVA. After LASSO regression analysis, we screened CD69, CDC25B, MGMT, TOP2A, and TXNIP as candidate genes. Among them, CD69 significantly influenced the overall survival of HCC patients in both TCGA and GSE76427. CD69 may be a protective factor for outcome of HCC patients. In addition, CD69 was positive correlation with T cells and CD3E. CD69, CDC25B, MGMT, TOP2A, and TXNIP were potential diagnostic and prognostic target for HCC, especially CD69.
引用
收藏
相关论文
共 50 条
  • [41] PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
    Honglei Feng
    Bole Li
    Ze Li
    Qian Wei
    Li Ren
    BMC Cancer, 21
  • [42] PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
    Feng, Honglei
    Li, Bole
    Li, Ze
    Wei, Qian
    Ren, Li
    BMC CANCER, 2021, 21 (01)
  • [43] EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis
    Gu, Fangming
    Yuan, Shengxian
    Liu, Lei
    Zhu, Peng
    Yang, Yuan
    Pan, Zeya
    Zhou, Weiping
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (06) : 4208 - 4216
  • [44] Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
    Maeda, Takahiro
    Kanzaki, Hiroaki
    Chiba, Tetsuhiro
    Ao, Junjie
    Kanayama, Kengo
    Maruta, Susumu
    Kusakabe, Yuko
    Saito, Tomoko
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Ogasawara, Sadahisa
    Suzuki, Eiichiro
    Ooka, Yoshihiko
    Nakamoto, Shingo
    Nakagawa, Ryo
    Muroyama, Ryosuke
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Naoya
    BMC CANCER, 2019, 19 (01)
  • [45] Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma
    Wang, Jianlin
    Xia, Congcong
    Pu, Meng
    Dai, Bin
    Yang, Xisheng
    Shang, Runze
    Yang, Zhen
    Zhang, Ruohan
    Tao, Kaishan
    Dou, Kefeng
    ONCOLOGY REPORTS, 2018, 40 (04) : 1875 - 1884
  • [46] FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma
    Zhen, Jing
    Pan, Jingying
    Zhou, Xuanrui
    Yu, Zichuan
    Jiang, Yike
    Gong, Yiyang
    Ding, Yongqi
    Liu, Yue
    Guo, Liangyun
    AGING-US, 2023, 15 (08): : 2937 - 2969
  • [47] Cisplatin resistance-associated circRNA_101237 serves as a prognostic biomarker in hepatocellular carcinoma
    Zhou, Shuping
    Wei, Juan
    Wang, Yeliu
    Liu, Xinkuang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 19 (04) : 2733 - 2740
  • [48] Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
    Takahiro Maeda
    Hiroaki Kanzaki
    Tetsuhiro Chiba
    Junjie Ao
    Kengo Kanayama
    Susumu Maruta
    Yuko Kusakabe
    Tomoko Saito
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Sadahisa Ogasawara
    Eiichiro Suzuki
    Yoshihiko Ooka
    Shingo Nakamoto
    Ryo Nakagawa
    Ryosuke Muroyama
    Tatsuo Kanda
    Hitoshi Maruyama
    Naoya Kato
    BMC Cancer, 19
  • [49] Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma
    Yu Jin
    Ye Shen Wong
    Brian K. P. Goh
    Chung Yip Chan
    Peng Chung Cheow
    Pierce K. H. Chow
    Tony K. H. Lim
    George B. B. Goh
    Thinesh Lee Krishnamoorthy
    Rajneesh Kumar
    Tze Pin Ng
    Samuel S. Chong
    Hwee Huang Tan
    Alexander Y. F. Chung
    London Lucien P. J. Ooi
    Jason P. E. Chang
    Chee Kiat Tan
    Caroline G. L. Lee
    Scientific Reports, 9
  • [50] Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma
    Jin, Yu
    Wong, Ye Shen
    Goh, Brian K. P.
    Chan, ChungYip
    Cheow, Peng Chung
    Chow, Pierce K. H.
    Lim, Tony K. H.
    Goh, George B. B.
    Krishnamoorthy, Thinesh Lee
    Kumar, Rajneesh
    Ng, Tze Pin
    Chong, Samuel S.
    Tan, Hwee Huang
    Chung, AlexanderY F.
    Ooi, London Lucien P. J.
    Chang, Jason P. E.
    Tan, Chee Kiat
    Lee, Caroline G. L.
    SCIENTIFIC REPORTS, 2019, 9 (1)